Paxlovid antiviral is being tested against permanent COVID-19
A clinical session is underway at Stanford University to see if Paxlovid antivirus is effective in treating permanent COVID-19. In fact, Paxlovid is admitted to be administered in the first phase of SARS-CoV-2 infection to prevent severe symptoms of COVID-19. Some studies suggest that this treatment decreases the risk of having a permanent COVID-19.
On the other hand, the mechanisms for developing permanent COVID-19 are not well known, but one hypothesis is that the virus would have to do with the persistence of the virus in some parts of the body.
Therefore, at the clinical session they want to test whether removing the virus through Paxlovid is effective in curing permanent COVID-19 or at least reducing symptoms. Volunteers, all with symptoms of permanent COVID-19, will take Paxlovid or placebo for 15 days and will then be monitored for its effectiveness.
Zu idazle
Zientzia aldizkaria
